SOAT1 and acute lymphoblastic leukemia: Since PIM kinase levels are regulated by the JAK/STAT pathway [64], we believe that the combination of TKI (Ponatinib) and PIM inhibitor (AZD1208/LGB321) will be effective in high-risk pediatric ALL cases, like ETP-ALL.